Automotive Anti-Pinch Power Window System Market to Reach $3,611.2 Million by 2023     |    Orthodontic Supplies Market to Reach $5.9 Billion by 2023     |    Automotive HMI Market to Reach $39,695 Million by 2023
P&S Market Research - A market research firm

Pancreatic Cancer Therapeutics Market

P&S Market Research-Pancreatic Cancer Therapeutics Market report

Global Pancreatic Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10902
Available Format: pdf

The global pancreatic cancer therapeutics market holds numerous opportunities for the key players, as pancreatic cancer is a highly challenging disease among all types of cancer, which has no specific treatment available for it, as of now. Also, growing incidence of cancer and technological advancements are supporting the growth of the global pancreatic cancer therapeutics market growth.

Cancer instigates uncountable growth of cells due to some abnormalities in the body. Some of the common symptoms of pancreatic cancer include weight loss, diarrhea, jaundice and abdominal pain. Cancer hampers the pancreas’ normal functioning, with smoking being the major risk factor for pancreatic cancer. Diagnosis of this type of cancer is done by patient history check and complete physical examination, followed by urine, stool and blood tests. Also, personal or family history of pancreatitis and BRCA2 mutation inclines a person to be affected by pancreatic cancer.

A number of imaging techniques such as MRI, ultrasound and CT scan are used for the disease diagnosis. The most common form of treatment is chemotherapy done by medical practitioners and oncologists. The drugs approved for the pancreatic cancer treatment include, but are not limited to ONIVYDE (irinotecan liposome injection); 5-FU (fluorouracil); Gemzar (gemcitabine); and ABRAXANE (albumin-bound paclitaxel). Apart from this, FOLFIRINOX, a combination of three chemotherapy drugs (5-FU/leucovorin, irinotecan, and oxaliplatin) is commonly used in the treatment of metastatic pancreatic adenocarcinoma. Other emerging treatments involve chemotherapies for advanced pancreatic cancer, combined with agents already approved for use, which are being investigated in clinical trials.

In developing countries, improvement in patient-centered care is being encouraged, as governments are investing huge amount of funds. Increasing elderly population base, high prevalence of pancreatic cancer and increase in foreign investments may be observed, over the forecast period, in the developing nations such as Asia-Pacific and Middle East Asia.

The global pancreatic cancer therapeutics market segments include type of affected region and application. The affected region segment is characterized into endocrine and exocrine. Maximum cases of pancreatic cancers diagnosed in the world belong to exocrine category, therefore, this segment presently leads the market. The endocrine segment of pancreatic cancers, though less prevalent, are still expected to have effective treatment modalities.

The investment in both segments of pancreatic cancers is significant. However, the growing prevalence and growing reach of novel techniques in the developing regions are the aspects likely to drive the growth of the exocrine category, throughout the forecast period.

Presently, the global pancreatic cancer therapeutics industry is merged in nature, with only a few top companies seizing the major share of the market. Some of the top companies operating in this market are Celgene Corporation; Eli Lilly and Company; Amgen, Inc.; F. Hoffmann-La Roche AG; PharmaCyte Biotech, Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Clovis Oncology; Pfizer, Inc.; and Merck & Co., Inc.

Several companies are concentrating on the introduction of technologically advanced products, in order to obtain a significant share in the fast-growing medical devices area. Also, collaborations, mergers and partnerships with well-established players are the key approaches followed by top players to increase their market share, during the forecast period.

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

Group License

Group License authorizes access of the publication upto 5 users.

Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.


Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment